TheStreet reiterated their buy rating on shares of Bristol-Myers Squibb (NYSE:BMY) in a research report sent to investors on Tuesday morning, Analyst RN reports.
“Bristol-Myers Squibb Company (BMY) has been reiterated by TheStreet Ratings as a buy with a ratings score of B. The company’s strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income.,” TheStreet’s analyst commented.
Shares of Bristol-Myers Squibb (NYSE:BMY) traded down 0.72% on Tuesday, hitting $48.59. 9,700,465 shares of the company’s stock traded hands. Bristol-Myers Squibb has a 52-week low of $36.03 and a 52-week high of $56.83. The stock’s 50-day moving average is $52.96 and its 200-day moving average is $48.59. The company has a market cap of $80.005 billion and a price-to-earnings ratio of 31.78.
Bristol-Myers Squibb (NYSE:BMY) last released its earnings data on Friday, January 24th. The company reported $0.53 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.43 by $0.10. The company had revenue of $4.44 billion for the quarter, compared to the consensus estimate of $4.30 billion. During the same quarter in the prior year, the company posted $0.47 earnings per share. The company’s quarterly revenue was up 6.0% on a year-over-year basis. Analysts expect that Bristol-Myers Squibb will post $1.77 EPS for the current fiscal year.
In other Bristol-Myers Squibb news, Director James Cornelius sold 100,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $48.90, for a total transaction of $4,890,000.00. Following the transaction, the director now directly owns 373,393 shares of the company’s stock, valued at approximately $18,258,918. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
Several other analysts have also recently commented on the stock. Analysts at Zacks reiterated a neutral rating on shares of Bristol-Myers Squibb in a research note to investors on Monday, January 27th. They now have a $53.00 price target on the stock. Separately, analysts at Argus raised their price target on shares of Bristol-Myers Squibb from $58.00 to $62.00 in a research note to investors on Wednesday, January 15th. They now have a buy rating on the stock. Finally, analysts at Barclays upgraded shares of Bristol-Myers Squibb from an equal weight rating to an overweight rating in a research note to investors on Friday, January 10th. They now have a $65.00 price target on the stock, up previously from $52.00. One analyst has rated the stock with a sell rating, six have assigned a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of Buy and an average price target of $53.36.
Bristol-Myers Squibb Company (NYSE:BMY) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis.
Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.